{"id":"NCT00297648","sponsor":"UCB Pharma","briefTitle":"Mucosal Healing Study in Crohn's Disease (CD)","officialTitle":"A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFÎ±) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-01","completion":"2009-12","firstPosted":"2006-02-28","resultsPosted":"2010-01-18","lastUpdate":"2011-08-31"},"enrollment":89,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab pegol","otherNames":["Cimzia","CZP","CDP870"]}],"arms":[{"label":"CDP870 400 mg","type":"EXPERIMENTAL"}],"summary":"The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.","primaryOutcome":{"measure":"Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments","timeFrame":"Baseline, Week 10","effectByArm":[{"arm":"CDP870 400 mg","deltaMin":-6.47,"sd":5.01}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":19,"countries":["Belgium","France","Germany"]},"refs":{"pmids":["24184736","22525883"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":89},"commonTop":["Headache","Arthralgia","Nasopharyngitis","Abdominal pain","Asthenia"]}}